Lipid‐Based Nanocarriers as Drug Delivery System and Its Applications

Jain, Vikas; Kumar, Hitesh; Chand, Pallavi; Jain, Sourabh; Preethi, S.

doi:10.1002/9781119711698.ch1

Cited by 13 publications

(10 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lipid-based nanocarriers, such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and nano-emulsions, are being utilized for the delivery and targeting of highly lipophilic drugs, including fisetin [ 83 ]. Kulbacka et al (2016) reported in their study that they prepared multifunctional SLNs loaded with cyanine-type IR-780 as a photosensitizer/diagnostic agent, along with fisetin or baicalein, to explore the potential of combination therapy in cancer eradication.…”

Section: Novel Formulation Strategies and Drug Delivery System Of Fis...mentioning

confidence: 99%

Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

Kumar

Bhatt

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies.

show abstract

Section: Novel Formulation Strategies and Drug Delivery System Of Fis...mentioning

confidence: 99%

Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

Kumar

Bhatt

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The incorporation of MT in lipophilic carrier system is employed to overcome many challenges such as modulation sustained drug release, reverse multidrug resistance (MDR), and improve its bioavailability [102,103]. To improve the therapeutic targeting of MT, Though et al developed Nanodiamonds (NDs) for the promising delivery of MT.…”

Section: Nano Formulation Development Strategy Of Mitoxantronementioning

confidence: 99%

Overview of Mitoxantrone-a Potential Candidate for Treatment of Breast Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

Anthraquinones are one of the popular classes of aromatic compounds which possess potential anticancer properties by suppressing the nucleic acid formation and proteins essential to the survival of cancerous cells. Mitoxantrone (MT) is an antibiotic and antineoplastic agent belonging to the anthracycline class of compounds which exhibit minimal incident of drug resistance. It is a synthetic anticancer drug, bound to enzyme topoisomerase IIα inhibitor, and intercalates DNA topoisomerase IIα, preventing re-ligations in DNA strands fragmentation and disruption of DNA repair. The expression of this enzyme was used tumor cells marker because of its key function in cell proliferation. The cleavable complex of topoisomerase IIα is hypothesized to damage the DNA and may enhance apoptosis in tumor cell proliferation. The susceptibility of cells to mitoxantrone is associated with cell topoisomerase II α protein and lowered resistance in breast cancer line cell lines to topoisomerase IIα inhibitors. MT is an ABC-transporter in breast cancer, also designated to be associated with “Breast cancer resistance protein” (BCRP) and it is also a cell cycle non-specific anti-cancer drug and P-glycoprotein substrate. Multiple drug resistance is one of the major drawbacks of this drug which can be avoided by reducing the efflux of the drug from cancer cells by formulating drug by using lipophilic carriers. This manuscript discusses about MT's source, chemistry, physicochemical properties, anti-cancer effects of mitoxantrone and possible pathways, Mitoxantrone targeting topoisomerase II inhibitor for cancer therapy and its mechanism, Various Nano formulation development strategy, toxicity profile, and a few patents related information.

show abstract

“…For topical delivery of medicines and chemotherapeutic drugs, several lipid nanocarrier systems are being used. However, the lipophilic characteristics of these drugs could suffer from targetability issues. , Recently, nanostructured lipid carriers (NLCs) were established as promising drug delivery vehicles. , NLCs are a novel generation of lipid nanocarrier systems that contain biphases of solid lipids and liquid lipids; hence, drug–lipid polymorphisms are prevented and can be stored for a longer time. , The inner core of NLCs comprises liquid lipids of medium-chain triglycerides, which can encapsulate lipophilic/hydrophilic drugs inside, whereas the outer surfaces comprise solid lipids of triglycerides, enabling surface modification . Surface-modified NLCs have advantages, i.e., insurance of biological applicability, sustained and controlled drug release, and safe delivery for in vivo administration …”

Section: Introductionmentioning

confidence: 99%

“…However, the lipophilic characteristics of these drugs could suffer from targetability issues. 19,20 Recently, nanostructured lipid carriers (NLCs) were established as promising drug delivery vehicles. 21,22 NLCs are a novel generation of lipid nanocarrier systems that contain biphases of solid lipids and liquid lipids; hence, drug−lipid polymorphisms are prevented and can be stored for a longer time.…”

Section: Introductionmentioning

confidence: 99%

Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

Kumar,

Chand,

Pachal

et al. 2023

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Fisetin (Fis), a natural flavonoid with anticancer effects, suffers from delivery constraints. Fisetin-nanostructured lipid carriers (NLCs) were developed for better efficacy against metastatic melanoma, employing the design of experiment (DoE) approach. The optimized NLCs depict a particle diameter of 135.0 ± 5.5 nm, a polydispersity index (PDI) of 0.176 ± 0.035, and an entrapment efficiency of 78.16 ± 1.58%. The formulation was stable over a period of 60 days and demonstrated sustained release of the drug (74.79 ± 3.75%) over 96 h. Fis-NLCs depicted at least ∼3.2 times lower IC 50 value and ∼1.8 times higher drug uptake at 48 h in A-375 and B16F10 cells compared to that of Fis. It also inhibited the mobility of melanoma cells and induced cell cycle arrest at the G1/S phase. Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot results show enhanced expression of Nrf2/NQO1 genes and an apoptotic effect by the upregulation of BAX mRNA expression. The protein levels of BAX and p53 were ∼2-fold higher compared with that of pure Fis. In-vivo studies demonstrated 5.9-and 10.7-fold higher inhibition in melanoma-associated metastasis in the lungs and liver, respectively. The outcomes from this study demonstrated Fis-NLCs as an effective tool against melanoma.

show abstract

Lipid‐Based Nanocarriers as Drug Delivery System and Its Applications

Cited by 13 publications

References 126 publications

Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics

Overview of Mitoxantrone-a Potential Candidate for Treatment of Breast Cancer

Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

Contact Info

Product

Resources

About